OPK - Opko Health, Inc.

Insider Purchase by Frost Phillip Md Et Al (CEO, COB, 10%)

6 Months
After Trade
Before Trade

Loading data...

Trade Summary

3 months ago, Frost Phillip Md Et Al, serving as CEO, COB, 10% owner at Opko Health, Inc. (OPK), purchased 580,000 shares at $1.33 per share, for a total transaction value of $771,328.00. Following this transaction, Frost Phillip Md Et Al now holds 249,822,576 shares of OPK.

The trade was executed on Thursday, November 20, 2025 and publicly disclosed via SEC Form 4 filing on Thursday, November 20, 2025, meaning the disclosure happened on the same day as the trade.

Opko Health, Inc. operates in the HEALTHCARE sector, specifically within the DIAGNOSTICS & RESEARCH industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Frost Phillip Md Et Al

Frost Phillip Md Et Al

CEO, COB, 10%

Phillip Frost, M.D. Director and 10% Owner, Cocrystal Pharma, Inc. (NASDAQ: COCP) Phillip Frost, M.D., is a seasoned physician and biotechnology executive with decades of leadership in the pharmaceutical industry. He currently serves as Chairman and Chief Executive Officer of OPKO Health, Inc. (NYSE: OPK), a position he has held since March 2007. Previously, Dr. Frost was Chairman of the Board of Teva Pharmaceuticals (NYSE: TEVA) and led IVAX Corporation as Chairman and CEO from 1987 until its acquisition by Teva in January 2006. Earlier in his career, he chaired Key Pharmaceuticals from 1972 to 1986, overseeing its growth and sale to Schering-Plough. A co-founder of Cocrystal Pharma, Inc., Dr. Frost brings extensive expertise in pharmaceutical development, commercialization, and strategic investments. At Cocrystal Pharma, Dr. Frost serves as a Director and 10% Owner, actively participating on the Audit, Compensation, and Nominating and Corporate Governance Committees. He has demonstrated strong commitment through recent insider transactions, including the acquisition of 20,000 shares on November 25, 2025, at an average price of $0.9406 via Frost Gamma Investments Trust (for which he is trustee), and an additional 4,000 shares on November 26, 2025, totaling approximately $3,975. These bring his indirect beneficial ownership to over 1.7 million shares through the trust and 27,100 shares directly (including restricted stock units). Dr. Frost also participated in a $1.03 million private placement in October 2025, underscoring his alignment with the company's antiviral drug pipeline advancements. Beyond corporate roles, Dr. Frost has contributed to prestigious institutions, including the Board of Regents of the Smithsonian Institution, the Board of Trustees of the University of Miami, and the Scripps Research Institutes. His board service extends to entities like Non-Invasive Monitoring Systems and Grove Bank & Trust, reflecting a broad impact in healthcare, finance, and governance.

View full insider profile →

Trade Price

$1.33

Quantity

580,000

Total Value

$771,328.00

Shares Owned

249,822,576

Trade Date

Thursday, November 20, 2025

94 days ago

SEC Filing Date

Thursday, November 20, 2025

HEALTHCAREDIAGNOSTICS & RESEARCH

About Opko Health, Inc.

Company Overview

No company information available
View news mentioning OPK

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/1299153

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime